0001558370-23-010549.txt : 20230526 0001558370-23-010549.hdr.sgml : 20230526 20230526163142 ACCESSION NUMBER: 0001558370-23-010549 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230522 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20230526 DATE AS OF CHANGE: 20230526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nutex Health, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41346 FILM NUMBER: 23969533 BUSINESS ADDRESS: STREET 1: 2455 EAST SUNRISE BLVD. STREET 2: SUITE 1204 CITY: FORT LAUDERDALE STATE: FL ZIP: 33304 BUSINESS PHONE: (954) 449-4703 MAIL ADDRESS: STREET 1: 2455 EAST SUNRISE BLVD. STREET 2: SUITE 1204 CITY: FORT LAUDERDALE STATE: FL ZIP: 33304 FORMER COMPANY: FORMER CONFORMED NAME: Clinigence Holdings, Inc. DATE OF NAME CHANGE: 20191113 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 8-K 1 nutx-20230522x8k.htm 8-K
0001479681false00014796812023-05-222023-05-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 22, 2023

 

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)

 

Delaware

001-41346

11-3363609

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(I.R.S. Employer
Identification Number)

​

‎6030 S. Rice Ave, Suite C, Houston, Texas 77081

(Address of principal executive offices) (zip code)

 

‎(713) 660-0557‎

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

 NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 22, 2023, Nutex Health Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 20, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(a)(2) if at any time before November 20, 2023 (the “Compliance Period”), the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten (10) consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company’s common stock.

The Company intends to continue actively monitoring the bid price for its shares of common stock between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency with every intention to regain compliance with the Minimum Bid Price Requirement.

If the Company does not regain compliance with Rule 5550(a)(2) by November 20, 2023, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, for example, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Nasdaq staff’s determination to delist its securities. There can be no assurance that the Company will be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing subsequent to any delisting notification.

Forward-Looking Statements

Certain statements and information included in this current report constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this current report, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including final rules implemented under the No Surprises Act and related regulatory guidance, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Company’s Annual Report on form 10-K for the year ended December 31, 2022 and its Current Report on Form 10-Q for the period ended March 31, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this current report.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

​

​

Date: May 26, 2023

​

Nutex Health Inc.

​

​

​

By: /s/ Jon C. Bates

​

Jon C. Bates

​

Chief Financial Officer

​

​

​

​

​

​

 EX-101.SCH 2 nutx-20230522.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 nutx-20230522_def.xml EX-101.DEF EX-101.LAB 4 nutx-20230522_lab.xml EX-101.LAB EX-101.PRE 5 nutx-20230522_pre.xml EX-101.PRE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 22, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date May 22, 2023
Entity Registrant Name NUTEX HEALTH INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-41346
Entity Tax Identification Number 11-3363609
Entity Address, Address Line One 6030 S. Rice Ave
Entity Address, Adress Line Two Suite C
Entity Address, City or Town Houston
Entity Address State Or Province TX
Entity Address, Postal Zip Code 77081
City Area Code 713
Local Phone Number 660-0557
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol NUTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001479681
Amendment Flag false
XML 7 nutx-20230522x8k_htm.xml IDEA: XBRL DOCUMENT 0001479681 2023-05-22 2023-05-22 0001479681 false 8-K 2023-05-22 NUTEX HEALTH INC. DE 001-41346 11-3363609 6030 S. Rice Ave Suite C Houston TX 77081 713 660-0557 false false false false Common Stock, $0.001 par value NUTX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://nutexhealth.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nutx-20230522x8k.htm nutx-20230522.xsd nutx-20230522_def.xml nutx-20230522_lab.xml nutx-20230522_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nutx-20230522x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "nutx-20230522_def.xml" ] }, "inline": { "local": [ "nutx-20230522x8k.htm" ] }, "labelLink": { "local": [ "nutx-20230522_lab.xml" ] }, "presentationLink": { "local": [ "nutx-20230522_pre.xml" ] }, "schema": { "local": [ "nutx-20230522.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nutx", "nsuri": "http://nutexhealth.com/20230522", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nutx-20230522x8k.htm", "contextRef": "Duration_5_22_2023_To_5_22_2023_fS2c6OtSsUqd0osjCLBy8w", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nutx-20230522x8k.htm", "contextRef": "Duration_5_22_2023_To_5_22_2023_fS2c6OtSsUqd0osjCLBy8w", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001558370-23-010549-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-010549-xbrl.zip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end